• Home
  • About Us
  • Diagnostics
    • Self-Testing
    • Point-of Care Testing
    • Companion Diagnostics
  • Technology
  • Partnership
  • News & Events
True Diagnostics True Diagnostics True Diagnostics True Diagnostics
  • Home
  • About Us
  • Diagnostics
    • Self-Testing
    • Point-of Care Testing
    • Companion Diagnostics
  • Technology
  • Partnership
  • News & Events

ABOUT US

True Diagnostics  creates powerful and simple solutions for the $46 billion and growing point-of-care, food safety, verification and animal health markets which are fast, portable, economical and risk-stratifying. With a small sample (e.g.,a finger prick of blood, a small urine or saliva sample or a surface wipe), the TrueDX Platform conducts qualitative and quantitative tests and provides laboratory quality results in minutes.

The TrueDX PlatformTM conducts qualitative and quantitative tests for life-threatening, quality of life and environmental conditions and provides laboratory quality results in minutes.

Performance & Growth

Countries around the world face mounting challenges in healthcare ranging from escalating costs and increased demand for patient access. Point-of-Care (POC) has become a critical component of the paradigm shift in providing affordable healthcare. In four years, it is expected the global market for point-of-care testing will reach $18.7 billion dollars. Our focus is on delivering a single diagnostic platform developed and validated through substantiated and reproducible test principles that employs new analytical methods to enable and realize this market opportunity.

Research & Development

Our partners and clients come to us for our experience and technical know-how. We have over 30 years of expertise in developing, manufacturing, and commercializing  immunoassays and molecular diagnostics. Our track record and proprietary library of reagents and materials allow us to deliver solutions to address:

  1. Optimized Precision
  2. Optimized Stability
  3. Sample Preparation
  4. Antibody Screening/Validation/Production (Monoclonal/Polyclonal/Peptides)
  5. Colorimetric Detection
  6. Fluorescence Detection
  7. Electrochemical Detection

Our development processes are performed under ISO 13485 and are fully design controlled and phased as outlined below.

Our Discovery & Development Capabilities

TruDia-about-bluehdr-01

– Reagent Production (Monoclonal/Polyclonal)
– Reagent Selection
– Prototype Reader

TruDia-about-bluehdr-02

– Prototype Cassette
– Prototype Assay
– Finalized Assay
– Finalized Cassette
– Finalized Reader
– Pre-Clinical Studies

TruDia-about-bluehdr-03

– Method Comparison
– CLIA Studies

Manufacturing & Support

True Diagnostics provides contract manufacturing services in a cGMP, FDA Licensed and ISO 13485 certified facility. Our company also provides regulatory expertise and consulting for the FDA Clearance and Support of medical devices.

Contact Us

Send us an email and we'll get back to you, asap.

Send Message

True Diagnostics, Inc. is a research, development and manufacturing company specializing in accurate, affordable and easy-to-use advanced rapid in-vitro immunodiagnostic test systems and reagents . The Company obtains licenses as a Medical Device Establishment by the United States Food and Drug Administration (FDA) and the State of California Department of Health Services, Food and Drug Branch, and receives FDA 510(k) approval for the products it offers.

Contact Info

  • True Diagnostics, Inc.
  • 2782 Loker Ave West • Carlsbad, CA 92010
  • 888-571-8597
  • info@truediag.com
  • truediag.com

© 2019 · True Diagnostics

  • Home
  • About Us
  • Diagnostics
    • Self-Testing
    • Point-of Care Testing
    • Companion Diagnostics
  • Technology
  • Partnership
  • News & Events